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ABSTRACT
Blockade of the inhibitory PD-1/PD-L1 immune checkpoint axis is a promising 
cancer treatment. Nonetheless, a significant number of patients and malignancies do 
not respond to this therapy. To develop a screen for response to PD-1/PD-L1 inhibition, 
it is critical to develop a non-invasive tool to accurately assess dynamic immune 
checkpoint expression. Here we evaluated non-invasive SPECT/CT imaging of PD-L1 
expression, in murine tumor models with varying PD-L1 expression, using high affinity 
PD-L1-specific nanobodies (Nbs). We generated and characterized 37 Nbs recognizing 
mouse PD-L1. Among those, four Nbs C3, C7, E2 and E4 were selected and evaluated 
for preclinical imaging of PD-L1 in syngeneic mice. We performed SPECT/CT imaging in 
wild type versus PD-L1 knock-out mice, using Technetium-99m (99mTc) labeled Nbs. Nb 
C3 and E2 showed specific antigen binding and beneficial biodistribution. Through the 
use of CRISPR/Cas9 PD-L1 knock-out TC-1 lung epithelial cell lines, we demonstrate 
that SPECT/CT imaging using Nb C3 and E2 identifies PD-L1 expressing tumors, but 
not PD-L1 non-expressing tumors, thereby confirming the diagnostic potential of the 
selected Nbs. In conclusion, these data show that Nbs C3 and E2 can be used to non-
invasively image PD-L1 levels in the tumor, with the strength of the signal correlating 
with PD-L1 levels. These findings warrant further research into the use of Nbs as a 
tool to image inhibitory signals in the tumor environment.
INTRODUCTION
Cancer cells express neo-antigens generated 
due to mutations and aberrant processing of proteins 
as well as cancer-germline antigens generated due to 
epigenetic alterations. Consequently, CD8+ T cells can 
recognize them as non-self [1]. However, cancer cells 
co-opt specific inhibitory signaling pathways, known as 
immune checkpoints to evade their CD8+ T cell-mediated 
destruction [2]. Inhibition of these inhibitory immune 
checkpoints has received increasing interest as a disruptive 
treatment for patients with solid and hematological tumors 
[3–16]. 
Several inhibitory immune checkpoints, consisting 
of inhibitory receptors expressed on T cells and their 
ligands expressed on antigen-presenting cells have been 
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described. Of these the immune checkpoint consisting 
of programmed death-1 (PD-1, CD279) and its ligand 
programmed death-ligand 1 (PD-L1, B7-H1, CD274), 
and its blockade with monoclonal antibodies (mAbs) have 
received much attention [7, 11, 15–19]. FDA approved 
mAbs targeting PD-1 include Nivolumab (Bristol-Myers 
Squibb) and Pembrolizumab (Merck), while Atezolizumab 
(Roche) is the first PD-L1 targeting mAb to be FDA 
approved [20].
Although treatment with antagonistic PD-1 and 
PD-L1 specific mAbs has shown encouraging 
results across different indications, a substantial 
number of patients do not respond. Therefore, there 
is a need to accurately predict which patients will 
benefit from this treatment. A number of correlative 
studies utilizing invasive biopsy in conjunction with 
immunohistochemistry (IHC) suggest that PD-1 
expression on tumor-infiltrating CD8+ T cells could serve 
as a predictive marker [21]. Similarly, the use of PD-L1 
expression in the tumor environment as a biomarker has 
been investigated. Indeed, across multiple cancer types, 
there is a strong positive correlation between pre-treatment 
PD-L1 expression (irrespective of its expression on tumor 
cells or infiltrating immune cells) and therapeutic response 
to PD-1/PD-L1 pathway inhibition [16]. Nonetheless, 
patients showing PD-1 or PD-L1 expression can fail 
anti-PD-1 or anti-PD-L1 mAb therapy, while patients 
that show no PD-L1 expression were reported to benefit 
from anti-PD-L1 mAb therapy [22]. This can be explained 
by the high heterogeneity of tumors and by the role that 
PD-L1 plays during antigen presentation to T cells by 
DCs [23, 24]. Both the expression of PD-1 and PD-L1 
are highly heterogeneous within the primary tumor as well 
as in metastases. Moreover, the expression of PD-1 and 
PD-L1 are likely to change in time and can be influenced 
by factors in the microenvironment, such as IFN-γ 
secretion [25]. Consequently, the static picture of a biopsy 
is not ideal to predict therapy outcome. IHC as a technique 
has the additional limitations that it does not provide 
information about the PD-1/PD-L1 expression in all 
lesions, and that it can only be performed on tumors that 
are accessible for biopsy. Therefore, there is a compelling 
need to develop a non-invasive imaging strategy to 
determine the presence of immune checkpoints in cancer 
patients before and during the course of treatment.
Imaging of PD-L1 or PD-1 using radiolabeled 
mAbs has recently been reported [26–31]. However, 
mAbs have inherent limitations that can curtail their 
efficacy as an imaging tool. Because of their size, they 
show poor capacity to penetrate tissue (tumor) and 
because of their long circulation time, high-contrast 
imaging can only be done after multiple days and with 
a risk of false positive results due to the remaining blood 
pool activity, especially for targets with low levels of 
expression like PD-L1 [32]. Therefore, there is a need 
for an alternative antigen-binding moiety with improved 
traits as a tracer. For instance, recent studies reported on 
the utility of small, affinity-matured compounds derived 
from the PD-1 extracellular domain as tracers to visualize 
(human) PD-L1 in the tumor as early as one hour after 
injection [33]. Likewise, Nanobodies (Nbs), which are the 
smallest antigen binding fragments that can be obtained 
from unique camelid heavy-chain-only antibodies, are 
attractive alternatives to mAbs. Nbs are stable, soluble 
and have a high specificity and affinity [34]. Furthermore, 
Nbs efficiently enter tissues where they rapidly and 
specifically bind their antigens, while unbound Nbs are 
quickly cleared through renal elimination. Consequently, 
Nb tracers usually generate higher target-to-background 
signals and earlier after administration as compared to 
mAbs [32].
In the current study, we developed tracers for 
preclinical imaging of PD-L1 using Nbs radiolabeled with 
technetium-99m (99mTc). To this end, a library of anti-
PD-L1 Nbs was screened and the identified anti-PD-L1 
Nbs were ranked according to affinity and specificity for 
human and/or mouse PD-L1. Four Nbs were selected and 
their biodistribution was evaluated in wild type and PD-L1 
knock out mice using SPECT/CT. Based on these results, 
two lead compounds were chosen for imaging of PD-L1 
in syngeneic tumors. These syngeneic mouse models 
enabled us to show that radiolabeled Nbs can visualize 
PD-L1 expression and that Nb accumulation correlates 
with levels of PD-L1 in the tumor, even when such PD-L1 
expression was low. The latter reflects the clinical situation 
where the threshold for PD-L1 positivity by IHC is low 
(often only 5%) [4]. Taken together, these results confirm 
the high potential of nanobody-based PD-L1 imaging and 
substantiate the development of anti-human PD-L1 Nbs 
for clinical translation.
RESULTS
Generation and selection of Nbs recognizing PD-L1
Nbs were raised against mouse PD-L1 by 
immunization of a dromedary with the PD-L1 expressing 
mouse macrophage cell line RAW264.7. Thirty-seven 
Nbs were selected after screening of an immune phage 
library on recombinant mouse PD-L1. Based on the amino 
acid sequence of the CDR1, 2 and 3 regions, these Nbs 
were divided into 9 sequence families (Supplementary 
Figure 1). Crude Nb-containing PEs were generated for 
further Nb characterization. The ability of the Nbs to bind 
mouse and human PD-L1 was determined in ELISA. 
The binding characteristics of the Nbs were compared 
using SPR measurements. Moreover, flow cytometry was 
performed to confirm binding to the mouse and human 
PD-L1 antigen when expressed on lentivirally modified 
B16 and HEK293T cells respectively (Supplementary 
Table 1). Nb families C and E bound particularly well 
on both mouse and human PD-L1 proteins with low 
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background, and Nbs C3, C7, E2 and E4 were chosen for 
further evaluation (Figure 1A).
The selected anti-PD-L1 and control Nbs were 
then produced and purified as C-terminally His6-tagged 
proteins from E. coli fermentation cultures. Quality 
control confirmed good purity and low LPS content 
(Table 1). The affinity (KD) of the purified Nbs for the 
immobilized mouse PD-L1 antigen was determined using 
SPR (Figure 1B). The KD values are in the low nanomolar 
range as shown in Figure 1 and Table 1. The ability of the 
different Nbs to bind to the mouse PD-L1 antigen when 
expressed on lentivirally modified HEK293T cells, was 
confirmed in flow cytometry (Figure 1C). We also used 
SPR to determine the affinity of the different Nbs for the 
human PD-L1 antigen. The affinity of the Nbs for the 
human PD-L1 antigen was substantially lower than for 
the mouse PD-L1 antigen (Supplementary Figure 2A). 
The ability of the different Nbs to bind to the human 
PD-L1 antigen when expressed on lentivirally modified 
HEK293T cells is shown in Supplementary Figure 2B.
Imaging of PD-L1 in naive mice
We radiolabeled the purified Nbs with 99mTc 
through complexation of the 99mTc-tricarbonyl with their 
His-tag. This is a site-specific labeling method with a 
low risk to interfere with their antigen binding capacity. 
Non-complexed 99mTc was removed by gel filtration and 
aggregates present within the eluted 99mTc-Nb preparation 
were removed by filtration. The radiochemical purity of 
the 99mTc-labeled Nbs was assessed by iTLC measurement 
and was > 98% (Table 1). 
To confirm their binding capacity and to distinguish 
specific from aspecific binding, the bio-distribution of 
each anti-PD-L1 Nb was compared in naive wild type and 
PD-L1 knock-out mice. SPECT/CT images taken 1 hour 
after intravenous tracer administration show high uptake 
in kidneys, bladder and to a certain extent also liver of 
wild type and knock-out mice (Figure 2A). 
The high signals in kidneys and bladder are 
explained by the known kidney retention and urinary 
excretion of all Nbs. Specific organ uptake was observed, 
and was further evaluated using dissection and γ-counting 
(Figure 2B), confirming specific uptake for all Nbs in 
lungs, heart, thymus, spleen, lymph nodes and brown 
adipose tissue in high contrast to uptake of the Nbs in 
the blood. The γ-counting data of all organs and tissues 
that was determined after intravenous delivery of the 
99mTc-labeled Nbs is shown in Supplementary Table 2. 
Tissue versus blood, anti-PD-L1 Nb versus control Nb 
uptake ratios in wild type mice, and tissue uptake ratios 
in WT versus PD-L1-knock-out mice after intravenous 
administration of 99mTc-labeled Nbs is shown in 
Supplementary Table 3. Nb C7 showed high and non-
specific uptake in liver and spleen, making it less attractive 
as an imaging agent. C3, a family member to C7, also 
showed non-specific liver uptake, although to a lesser 
extent than C7. For the E-family members, the difference 
in organ uptake between wild type and PD-L1 knock-out 
mice is more pronounced for E2 than for E4.
Except for the accumulation of the Nbs in brown 
adipose tissue, we expected this biodistribution profile, 
because expression of PD-L1 on cardiac endothelium 
and cells of hematopoietic origin present within lung, 
spleen, thymus and lymph nodes has been well established 
[35–37]. However, the expression of PD-L1 in brown 
adipose tissue has only been recently described [31]. 
Therefore, we performed flow cytometry to analyze 
the expression of PD-L1 in brown adipose tissue, and 
compared it to PD-L1 expression on cells isolated from 
the spleen and lymph nodes. We observed that a high 
percentage of cells in these tissues expressed PD-L1 
(Figure 2C).
Detection of PD-L1 in tumor bearing mice
To determine whether anti-PD-L1 Nbs are able to 
detect differences in PD-L1 expression in tumors, we set 
out to generate a model with low and high mouse PD-L1 
expression. Hereto, we transduced TC-1 lung epithelial 
cells with lentiviral vectors that harbor the murine PD-L1 
gene or a shRNA targeting mouse PD-L1 to generate a 
PD-L1 knock-in and knock-down TC-1 model 
respectively. Expression of PD-L1 on TC-1 wild type, 
knock-down and knock-in cells was evaluated by flow 
cytometry, showing < 20% to nearly 100% of cells 
expressing PD-L1 in the PD-L1 knock-down and knock-
in TC-1 cells respectively (Figure 3A). 
The PD-L1 knock-down and knock-in TC-1 cells 
were transplanted subcutaneously in wild type mice, and 
tumor growth was evaluated every other day. We observed 
a delayed outgrowth of TC-1 tumors in the PD-L1 knock-
down model, highlighting the critical role of PD-L1 in 
tumor development (Figure 3B). We performed SPECT/
CT imaging 1 hour after injection of the 99mTc-labeled Nbs 
C3 and E2, followed by evaluation of accumulation of 
these Nbs in individual organs (ex vivo analysis). Against 
our expectations, in vivo and ex vivo analysis showed the 
highest accumulation of both Nbs in tumors grown from 
the PD-L1 knock-down TC-1 cells (Figure 3D–3E). 
Dissection and biodistribution data obtained at 80 
minutes after Nb injection using γ-counting is shown 
in Supplementary Table 4 (on the left), confirm these 
findings. Tissue-to-blood ratios of all organs derived 
from the biodistribution data are shown in Supplementary 
Table 5 (on the left). To further investigate the cell type 
being targeted, we isolated tumors grown from the 
PD-L1 knock-down and knock-in TC-1 cells and evaluated 
the expression of PD-L1 by flow cytometry. In accordance 
with the imaging data, flow cytometry showed a 
significantly higher expression of PD-L1 in tumors grown 
from the PD-L1 knock-down cells. This was observed 
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on both immune (CD45+) and non-immune (CD45−) 
cells, suggesting that the shRNA expressed in these 
cells is inefficient in mediating substantial knock-down 
of PD-L1 in vivo and a compensatory upregulation of 
PD-L1 expression on immune infiltrates (Figure 3C). 
We hypothesize that initially the expression of PD-
L1 is low in tumors of wild type mice inoculated with 
PD-L1 knock-down TC-1 cells, thereby allowing CD8+ 
T cells to interact with the tumor cells unhampered. 
Consequently, these CD8+ T cells produce IFN-γ and keep 
the tumor growth under control. Indeed, tumor growth 
is less pronounced in this situation (Figure 3B). Since 
production of IFN-γ leads to the expression of interferon-
inducible immune suppressive factors such as PD-L1, we 
hypothesized that the shRNA targeting PD-L1 in tumor 
cells is not potent enough to mediate degradation of the 
newly transcribed mRNA. To evaluate this hypothesis, 
we treated PD-L1 knock-down TC-1 cells with 50 or 
100 ng/ml IFN-γ in vitro and showed upregulation of 
PD-L1 in flow cytometry (Supplementary Figure 3A). 
We furthermore inoculated wild type mice that were 
depleted of CD8+ T cells with PD-L1 knock-down TC-1 
cells. Tumor growth and PD-L1 expression on cancer and 
immune cells was evaluated. Tumor growth was enhanced 
in mice depleted of CD8+ T cells (Supplementary Figure 
3B). Expression of PD-L1 was significantly lower on both 
immune cells and cancer cells in mice lacking CD8+ T 
cells (Supplementary Figure 3C), suggesting that indeed 
CD8+ T cells induce PD-L1 expression most likely 
through secretion of IFN-γ.
Figure 1: Selection of anti-mouse-PD-L1 specific Nbs. (A) Amino acid sequence alignment of the purified Nbs C3, C7, E2 and 
E4. The Nb sequence includes three complementarity-determining regions (CDR 1, 2, 3; indicated in red) and four framework regions 
(FR1-4, indicated in black). FRs are relatively conserved but CDRs vary widely among Nbs. (B) Affinity/kinetics SPR study of purified 
Nbs interacting with immobilized His-tagged recombinant mouse PD-L1 protein. Sensorgrams of different concentrations of the Nbs are 
shown (n = 1). (C) Representative flow cytometry results, showing staining of unmodified HEK293T cells (grey line) or HEK293T cells 
lentivirally modified to express mouse PD-L1 (293T moPD-L1, red line) with mAbs specific for mouse PD-L1 or Nbs C3, C7, E4 and E2 
(n = 3).
Table 1: Summary of the endotoxin content, affinity for mouse PD-L1 and radiochemical purity of 
99mTc-Nb complexes of purified anti-PD-L1 Nbs C3, C7, E4 and E2
Nb Endotoxins  (EU/ml) Affinity (KD) Radiochemical  purity
C3 < 50 0.5 nM 98.7
C7 < 50 17.0 nM 98.8
E2 59 2.1 nM 98.4
E4 67 4.0 nM 99.0
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Despite the more complex interpretation of the data 
in Figure 3, these results do suggest that Nb C3 and E2 
can be used to detect differences in PD-L1 expression 
in tumors. To further confirm the diagnostic potential 
of these Nbs in a more clear-cut PD-L1-negative tumor 
model, we decided to take an alternative approach and 
knocked out PD-L1 in TC-1 cells using the CRISPR/
Cas9 technology. Knock-out of PD-L1 on these TC-1 
cells, even in the presence of IFN-γ, was shown in vitro 
by flow cytometry, in contrast to TC-1 knock-down cells, 
which show upregulation of PD-L1 as a response to IFN-γ 
(Figure 4A). To generate a PD-L1 positive tumor model, 
we transplanted wild type TC-1 cells subcutaneously in 
wild type mice, while we transplanted PD-L1 knock-
out TC-1 cells to PD-L1 knock-out or wild type mice to 
generate a PD-L1 negative tumor model. Initially tumor 
growth was observed in all conditions. 
However, from day 7 onwards tumors grown from 
the PD-L1 knock-out TC-1 cells in PD-L1 knock-out mice 
(Figure 4B) as well as in wild type mice (data not shown) 
regressed, again showing the central role of intratumoral 
PD-L1 expression in tumor development. To evaluate 
whether the tumor regression was due to an adaptive 
immune response, we performed an antibody-mediated 
depletion of CD8+ cells in PD-L1 knock-out mice prior 
to their inoculation with PD-L1 knock-out TC-1 cells. 
The depletion of CD8+ T cells was repeated at a three-day 
interval and was confirmed by flow cytometry (Figure 4C). 
Tumor growth was observed in these mice, while no tumor 
growth was observed in mice treated with isotype matched 
control antibodies (Figure 4D). We then compared by 
flow cytometry the expression of PD-L1 in these tumors 
to the expression of PD-L1 in tumors grown from TC-1 
wild type cells in wild type mice. We showed that PD-L1 
knock-out TC-1 tumors grown in CD8+-depleted PD-L1 
knock-out mice had much lower PD-L1 expressing cells 
than wild type TC-1 tumors grown in wild type mice 
(Figure 5B), although the percentage PD-L1 positive cells 
in the latter tumors was rather low (similar to tumors in 
patients). 
This model was used to perform SPECT/CT imaging 
1 hour after injection of the 99mTc-labeled Nbs C3 and E2, 
followed by evaluation of Nb accumulation in individual 
organs. Dissection and biodistribution data obtained at 
80 minutes after Nb injection using γ-counting is shown 
in Supplementary Table 4 (on the right). Tissue-to-blood 
ratios of all organs, derived from the biodistribution data, 
are shown in Supplementary Table 5 (on the right). When 
analyzing the images, signals were especially observed at 
the periphery of the tumor in the PD-L1 positive tumor 
model. In contrast, the PD-L1 negative model showed 
lower signal in the tumor (Figure 5A). Remarkably, in the 
Figure 2: SPECT/CT and biodistribution evaluated 1 hour after injection of 99mTc-Nbs C3, C7, E4 or E2 in naive wild 
type (WT) and PD-L1 knock out (KO) mice. (A) Results of SPECT/CT scans to determine the biodistribution of 99mTc-Nbs C3, C7, 
E4 or E2 injected in WT or PD-L1 KO mice (n = 3). (B) Gamma counting of isolated organs from WT or KO mice injected with 99mTc-Nbs 
C3, C7, E4 or E2. The graph summarizes the organ uptake of the Nb per gram organ as the mean ± SEM (n = 3). (C) Percentage PD-L1 
positive cells in spleen, lymph node (LN) and brown adipocyte tissue (BAT) of WT and PD-L1 KO mice using flow cytometry. The graph 
summarizes the percentage PD-L1 positive cells as mean ± SEM (n = 3). K = kidney, L = liver, S = spleen, B = bladder, BAT = brown 
adipocyte tissue.
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ex vivo analysis, significantly higher uptake of Nb C3, but 
not E2, in the TC-1 wild type tumor model compared to the 
TC-1 knock-out tumor model was detected (Figure 5C). 
We then quantified ROI values at the periphery of 
the tumor to assess the accuracy of the 99mTc-labeled Nbs 
to imagine PD-L1 expression levels in the tumor. These 
data revealed higher uptake of the Nb at the periphery 
of the tumor in TC-1 wild type tumors, where PD-L1 
was expressed albeit at a rather low level, compared to 
the TC-1 knock-out tumors, where PD-L1 expression 
was almost negative (Figure 5D). These data confirmed 
the heterogeneity of PD-L1 expression in the tumor and 
showed that Nbs can be used to visualize PD-L1 in the 
tumor, even when PD-L1 expression is low, representing 
the clinical situation. These data confirm the importance to 
develop a non-invasive tool to evaluate PD-L1 expression 
in cancer patients before and during treatment.
DISCUSSION 
Relevance of the study
Several immune checkpoint inhibitors targeting the 
PD-1/PD-L1 axis have been FDA approved because they 
have yielded unprecedented progression-free survival in a 
number of late stage cancer patients [7, 11, 20]. However, 
Figure 3: SPECT/CT in the shRNA-modified TC-1 model 1 hour after injection of 99mTc-Nbs C3 or E2. (A) Percentage 
of PD-L1 on TC-1 cells transduced with lentiviral vectors harboring shRNA against mouse PD-L1 (knock-down, KD), wild type TC-1 
cells (WT) or TC-1 cells transduced with mouse PD-L1 (knock-in, KI), evaluated with flow cytometry (n = 5). The graph summarizes the 
percentage PD-L1 positive cells as mean ± SEM. (B) TC-1 KD or KI cells were injected subcutaneously at the tail base of C57BL/6 mice. 
Tumor growth was followed every other day. The evolution of tumor size is shown as mean ± SEM (n = 5). (C) Mice were sacrificed on 
day 12 and tumors were isolated, after which expression of PD-L1 on tumor cells (CD45- , white bar)  and tumor-infiltrating immune cells 
(CD45+, black bar) was evaluated in flow cytometry. The graph summarizes the percentage of PD-L1 as mean ± SEM (n = 5). (D) Images 
of SPECT/CT scans to determine the accumulation of 99mTc-Nbs C3 and E2 in C57BL/6 mice bearing KI (left panel) or KD (right panel) 
tumors (n = 6). The red arrow indicates the tumor on the images. (E) Graphs showing the quantified ex vivo analysis to determine the 
accumulation of 99mTc-Nbs C3 and E2 in PD-L1 KI (black bar) or KD (white bar) tumors. The graph shows the percentage radioactivity 
per gram tumor as mean ± SEM (n = 6). 
Oncotarget7www.impactjournals.com/oncotarget
despite encouraging clinical results, a significant number 
of cancer patients do not respond to the therapy. It is 
believed that lack of PD-1/PD-L1 checkpoint expression 
is at least for a subset of these non-responders responsible 
for the therapy failure. Therefore, there is a compelling 
need to develop tools to visualize the PD-1/PD-L1 axis 
and predict which patients are likely to respond to PD-1/
PD-L1 blocking immunotherapy.
Currently, IHC is applied to measure and evaluate 
PD-L1 expression [4, 38]. However, IHC has several 
limitations, as it is an invasive technique that does 
not allow visualizing the heterogeneous expression of 
PD-L1 in primary tumors. Furthermore, given the 
dynamic nature of PD-L1 expression during the disease 
course and in reaction to treatment, repeated biopsies 
with associated cumulative risks are necessary to fully 
Figure 4: Use of the CRISPR/Cas9 technology to generate a PD-L1 KO tumor model. (A) Percentage of PD-L1 as assessed 
with flow cytometry on TC-1 cells transduced with lentiviral vectors harboring CRISPR/Cas9 targeted to mouse PD-L1 (knock-out, KO) 
compared to WT and KD TC-1 cells either or not pre-treated with recombinant mouse IFN-γ (50 ng/mL) (n = 3). The graph summarizes 
the percentage PD-L1 positive cells as mean ± SEM. (B) TC-1 KO or WT cells were injected subcutaneously at the tail base of WT or PD-
L1 KO mice. Tumor growth was followed every other day. The tumor size in function of time is shown as mean ± SEM (n = 3). (C) TC-1 
KO cells were injected subcutaneously at the tail base of PD-L1 KO mice, which were pretreated with a CD8+ depleting antibody or an 
isotype matched control antibody. The percentage CD8 positive cells in the blood was evaluated using flow cytometry. The graph shows a 
representative histogram of CD8 positive cells in mice pretreated with an isotype matched control antibody (grey line) or a CD8 depleting 
antibody (red line). (D) TC-1 KO cells were injected subcutaneously at the tail base of PD-L1 KO mice, which were pretreated with a CD8+ 
depleting antibody or an isotype matched control antibody. WT TC-1 cells were injected subcutaneously at the tail base of WT mice. Tumor 
growth was followed every other day. The tumor size in function of time is shown as mean ± SEM (n = 3). 
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capture the role of PD-L1 in predicting treatment 
response. Isotope-based imaging such as PET and SPECT 
is a non-invasive technique that allows repetitive image-
based characterization of primary and metastatic lesions 
independent of their location. This has been shown for 
multiple cancer cell associated antigens, that are typically 
abundantly available on the tumor cell membrane [39–43]. 
The challenge is however much greater if the antigen is 
present at lower levels and only on a subset of tumor cells. 
It remains to be proven that also there, nuclear medicine 
can accurately assess antigen expression levels.
Rationale to use Nbs for the imaging of immune 
checkpoints
We report on the generation and selection of Nbs for 
quantitative, non-invasive in vivo imaging of the inhibitory 
ligand PD-L1. Compared to monoclonal antibodies, 
Nbs show superior imaging characteristics, with fast 
blood clearance resulting in high contrast images within 
only hours after injection of the tracer, as was recently 
shown in a clinical trial using anti-HER2 Nbs for PET/
CT imaging [44]. When full monoclonal antibodies are 
used for imaging, imaging is typically performed after 4 
to 6 days, resulting in the use of long-lived isotopes and 
increased radiation exposure to the subject [45]. Even at 
these time points, remaining non-specific signal due to 
uncleared tracer in the blood could result in insufficient 
accuracy to correctly assess low-expressed targets such 
as PD-L1. We are therefore convinced that anti-PD-L1 
Nbs offer important advantages compared to radiolabeled 
antibodies for imaged-based characterization of lesions. 
Nbs C3 and E2 were selected as lead compounds 
based on their antigen-specificity, nanomolar affinity and 
distribution in healthy mice, showing accumulation in 
the lungs, heart, thymus, spleen, lymph nodes and brown 
adipose tissue, next to kidneys, bladder and liver. 
The signals in kidneys and urinary bladder are 
observed in all mice and is a typical feature of Nbs, as they 
are cleared by renal uptake and elimination due to their 
small size [46]. The signals in liver are partially specific 
and partially aspecific. We observed that the liver retention 
differs between the C- and E-family with higher signals 
observed for Nb C3 than for Nb E2. This can be explained 
by the Nb composition, which determines its metabolism 
and as such the degree of liver uptake. The specific signals, 
showing distribution of the Nbs in lungs, heart, thymus, 
spleen, lymph nodes and brown adipose tissue, was 
previously described using mAbs as a tracer [31]. This 
distribution is linked to the role of the PD-1/PD-L1 immune 
Figure 5: SPECT/CT in the CRISPR/Cas9-modified TC-1 model 1 hour after injection of 99mTc-Nbs C3 or E2. 
(A) Images of the SPECT/CT scans to evaluate 99m Tc-Nbs C3 and E2 for tumor stratification in CD8-depleted PD-L1 KO mice bearing 
PD-L1 KO tumors (KO) or WT mice bearing WT (PD-L1+) tumors (WT) (n = 6). The red arrow indicates the tumor on the images. 
(B) CD8-depleted PD-L1 KO mice injected with PD-L1 KO tumors or WT mice injected with WT (PD-L1+) TC-1 cells were sacrificed on 
day 17 and tumors were isolated, after which expression of PD-L1 on cancer cells (CD45−, white bar) and tumor-infiltrating immune cells 
(CD45+, black bar) was evaluated in flow cytometry. The graph summarizes the percentage of PD-L1 as mean ± SEM (n = 6). (C) Results 
of the gamma counting of isolated organs from CD8-depleted PD-L1 KO mice bearing PD-L1 KO tumors (KO, white bars) or WT mice 
bearing WT (PD-L1+) tumors (WT, black bars) injected with 99Tm Tc-Nbs C3 and E2. The graph summarizes the %IA/g as mean ± SEM 
(n = 6). (D) Tumor uptake (%ID/cc) calculated via ROI analysis on the periphery of the tumor from CD8-depleted PD-L1 KO mice bearing 
PD-L1 KO tumors (KO, white bars) or WT mice bearing PD-L1+ tumors (WT, black bars) injected with 99Tm Tc-Nbs C3 and E2. The graph 
summarizes the %ID/cc as mean ± SEM (n = 6). 
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checkpoint, which under healthy conditions is at work 
during the induction of peripheral T cell self-tolerance and 
in limiting effector T cell induction [47, 48]. The uptake in 
brown adipose tissue has only recently been observed, and 
was confirmed by our imaging experiments [31].
Development of models to evaluate Nb tracers 
with high potential for imaging
To study the Nbs as tracers to detect PD-L1 
expression in tumors, we set out to generate in vivo 
tumor models with low and high PD-L1 expression. We 
used the tumor cell line TC-1, a lung epithelial cell line, 
because we previously showed that TC-1 cells expresses 
PD-L1 and exploit this mechanism to counteract effector 
T cells that express high levels of PD-1 [49]. Moreover, 
in the clinic it was shown in lung cancer that responses 
to anti-PD-L1 and PD-1 treatment correlate with 
PD-L1 expression in the tumor [4]. First, we used the 
RNAi technology to knock-down PD-L1 expression. 
Growing these cells in immunocompetent wild type mice 
confirmed the critical role of PD-L1, as the shRNA-
modified TC-1 cells progressed slower than the PD-L1 
overexpressing TC-1 cells. Against our expectations, we 
observed higher accumulation of the Nbs in tumors grown 
from shRNA-modified TC-1 cells. Using flow cytometry, 
we confirmed that a higher percentage of immune and 
tumor cells expressed PD-L1. We hypothesize that the 
unexpected high expression of PD-L1 in this model can be 
explained as follows: initially shRNA-modified TC-1 cells 
show low PD-L1 expression, and as such are infiltrated 
with CD8+ T cells that are unhampered in their ability 
to produce IFN-γ. As IFN-γ triggers the transcription of 
PD-L1 [25], the tumor cells will produce an abundant 
amount of PD-L1 mRNA. Most likely, the shRNA is not 
efficient enough to tackle the abundance of PD-L1 mRNA. 
Consequently, the tumor cells become PD-L1 positive. It 
is indeed described that PD-L1 is up-regulated to mediate 
resistance to an adaptive immune response [50]. We 
were able to show the important role of tumor-infiltrating 
lymphocytes and their IFN-γ secretion in the local PD-L1 
expression on tumor cells. Therefore, we  inoculated wild 
type mice that were depleted of CD8+ T cells with PD-L1 
knock-down tumor cells. We observed that the expression 
of PD-L1 was significantly lower on both immune cells 
and cancer cells in mice lacking CD8+ T cells, suggesting 
that indeed CD8+ T cells induce PD-L1 expression most 
likely through secretion of IFN-γ. 
We then altered our strategy and used the CRISPR/
Cas9 technology to knock out PD-L1. In vitro, we showed 
that even in the presence of IFN-γ, PD-L1 expression was 
low. When growing these tumor cells in PD-L1 knock-
out mice, we observed palpable tumors at day 7, which 
regressed later on. This was unexpected as the CRISPR/
Cas9 technology has been previously used to generate PD-
L1 knock-out tumor cells or PD-1 negative T cells without 
hampering tumor growth or viability [31, 51]. This 
observation again highlights the critical role of PD-L1 in 
the development of the TC-1 lung epithelial tumors. We 
hypothesized that tumors lacking PD-L1 were most likely 
rejected by infiltrating CD8+ T cells that are unhampered 
in their activity. Therefore, we depleted the CD8+ T cells 
using a CD8 depleting antibody. We observed tumor 
growth, thereby validating our hypothesis. Moreover, we 
showed that these tumors were void of PD-L1 expressing 
cells. 
When evaluating the 99mTc-labeled lead Nbs as a 
tracer in TC-1 tumors with varying PD-L1 expression, we 
observed that the strength of the signal on the SPECT/
CT images correlated well with the levels of PD-L1 
expression ex vivo evaluated using flow cytometry, for the 
knock-down tumor model. This model had relatively high 
level of PD-L1 expressing cells in the tumor, typically 
between 30 and 50%. 
Using the knock-out tumor model, the level of 
PD-L1 expressing cells was much lower, on average 
around 8% of cells in the positive tumor and below 
2% in the negative tumor model. However, even in 
this low-expressing model, this small difference in 
expression levels was visually discernable as a high 
uptake at the periphery of the tumor and confirmed by 
image quantification. Using ex vivo quantification of the 
radioactive content of the entire tumor, the difference was 
only retained for Nb C3, but not for E2, probably because 
the uptake is averaged out over the entire tumor rather than 
looking at the focal expression. Given the better results of 
C3 compared to E2 in this low level expression model, C3 
is selected as the lead compound with the highest potential 
to correctly assess clinically relevant differences in PD-L1 
expression levels. As such, these Nbs with a high affinity 
for mouse PD-L1 are suited to evaluate the critical role 
of PD-L1 in immunocompetent mice bearing syngeneic 
tumor models.  Unfortunately, the selected Nbs do not 
show sufficient cross-reactive binding to human PD-L1 for 
clinical translation. Therefore, there is a need to validate 
Nbs that bind with high affinity to human PD-L1 as a 
diagnostic tool for the selection of patients.
Other research teams have developed imaging 
strategies for PD-1 or PD-L1 in the recent past. Multiple 
have investigated mAbs as imaging agents, with 
disadvantages associated with the slow blood clearance 
of such tracers [26–31]. A recent study used high-affinity 
consensus (HAC)-PD-1 radiotracer variants to image 
PD-L1 expression in the tumor as early as one hour 
after injection. These radiotracers, with a size of 14 kDa 
and a dissociation constant of 100 pM, were tested in a 
human CT26 PD-L1 negative tumor model and tumor 
model engineered to constitutively express human 
PD-L1. These tracers were the first engineered binders 
to distinguish between PD-L1 positive and negative 
tumors. The properties of these radiotracers are close to 
the properties of Nbs, as Nbs have a size of 15 kDa and 
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bind with nanomolar affinity to their target. The here-
presented Nbs are less cross-reactive to human PD-L1 
than some of the HAC-PD-1 tracer variants. The HAC-
PD-1 variants showed non-specific background signal in 
liver and spleen, which we also observed with our Nbs. 
However, these tracers showed a lower tumor-to-blood 
ratio compared to our Nbs. Furthermore, the difference in 
uptake between the negative and positive PD-L1 tumor is 
rather lower for the HAC-PD-1 variant [33].
In conclusion, we show that Nbs can be used to non-
invasively and quantitatively image PD-L1 in the tumor 
as soon as 1 hour after its injection. In addition, they can 
be used to evaluate the critical role of PD-L1 in syngeneic 
tumor models, resembling the patient’s situation. 
Moreover, this study provides a rationale to further 
develop Nbs that bind human PD-L1 as a diagnostic tool 
for patient selection and potentially treatment monitoring, 
as Nb radiotracers exhibit many favourable imaging 
characteristics.
MATERIALS AND METHODS
Reagents
Anti-HA mAb (Biolegend, clone 16B12) was used 
in ELISA and in flow cytometry to detect HA-tagged 
Nbs in periplasmic extracts (PEs); anti-His mAb (AbD 
Serotec, clone AD1.1.10), followed by a phycoerythrin 
labeled anti-mouse IgG antibody (BD biosciences, clone 
A85-1), was used in flow cytometry to detect binding 
of purified His-tagged Nbs. All Biacore consumables 
were from GE Healtcare. Recombinant mouse PD-L1 
protein (Sino Biological #50010-M08H) was used for 
biopanning and initial enzyme-linked immunosorbant 
assay (ELISA) screening. Mouse or human PD-L1 Fc-
fusion proteins (R&Dsystems, 1019-B7 and 156- B7 
respectively) were used for calibration-free concentration 
analysis (CFCA) and affinity estimations of the Nbs in 
PEs. Mouse or human PD-L1 His-tagged proteins (Sino 
Biological #50010-M08H and #10084-H08H) were used 
for ELISA screenings of Nbs in PEs and Surface Plasmon 
Resonance (SPR) affinity determinations on purified Nbs. 
A phycoerythrin labeled antibody specific for mouse PD-
L1 (Biolegend, 10F.9G2) or an allophycocyanin labeled 
antibody specific for human PD-L1 (eBioscience, MIH5) 
was used in flow cytometry to evaluate PD-L1 expression 
on cells in vitro. Furthermore, an HorizonV450 labeled 
antibody specific for mouse CD45 (Biologend, 30-F11) 
and a phycoerythrin labeled antibody specific for mouse 
PD-L1 (Biolegend, 10F.9G2) was used to evaluate PD-L1 
expression in flow cytometry.
Isolation of PD-L1-specific Nbs
A dromedary was subcutaneously immunized 
5 times bi-weekly, each time with 10 million RAW264.7 
cells. Peripheral blood lymphocytes were purified and 
used as a source to create a Nb-phage display library as 
described previously [52]. Mouse PD-L1 reactive Nbs 
were identified by biopanning of this library and ELISA 
screenings of PEs of individual Nb clones on recombinant 
mouse PD-L1 protein, and sequence analysis following 
published protocols [52].
Periplasmic extractions of small-scale cultures
PEs were produced as described [53]. Briefly, 
E.coli WK6 cells were transformed with Nb-coding 
pHEN4 plasmids and cultured in 10 mL Terrific broth 
(TB) containing 100 µg/mL Ampicillin (Fermentas) for 
6h at 37°C. Nb expression was induced overnight with 
1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) while 
shaking at 200 rpm. Cultures were centrifuged for 10 min 
at 1643xg and 4°C, after which the bacterial pellet was 
frozen at −80°C. One day later, 2 mL phosphate buffered 
saline (PBS, Sigma-Aldrich) was added to the thawed 
bacterial pellets and pellets were stirred for 30 min at 
4°C. The released periplasmic proteins were collected by 
centrifugation for 20 minutes at 730 × g and 4°C, followed 
by 0.22 µm filtration (Millipore). 
These PEs were used to evaluate interaction with 
mouse and human PD-L1 (i) in ELISA to assess qualitative 
binding to immobilised recombinant PD-L1 proteins; (ii) 
using SPR to rank Nbs for binding to recombinant PD-
L1 proteins; (iii) in flow cytometry to assess binding to 
HEK293T cells transfected with PD-L1 cDNAs. ELISA 
on PEs are performed as described elsewhere [52]. SPR 
and flow cytometry analyses of PEs are described below.
Large-scale production, purification and quality 
control of Nbs
cDNAs of selected Nbs were recloned into the vector 
pHEN6 to encode a C-terminal His6 tag. Also Nb BCII10 
and R3B23, specific for bacterial β-lactamase and 5T2 
multiple myeloma paraprotein respectively, were produced 
and used throughout the study as negative controls [54]
[55]. All Nbs were produced and purified in PBS as 
described previously [52]. Protein purity was assayed 
by 12% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) under reducing conditions, 
followed by staining with Coomassie Blue. Endotoxins 
were measured in the LAL (Limulus amebocyte lysate 
assay). The latter was performed as recommended by the 
manufacturer (PierceTM LAL Chromogenic Endotoxin 
Quantification Kit, Thermofisher). 
Surface plasmon resonance
All measurements were performed on a Biacore 
T200 device (GE Healtcare) at 25°C and using 
Hepes-buffered saline (HBS; 0.01 M HEPES pH 7.4, 
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0.15 M NaCl, 3 mM EDTA, 0.005% Tween 20) as running 
buffer. All recombinant proteins were dissolved to 
10 ug/mL in 10mM Na-acetate pH 5.0 for 
immobilization on a CM5 sensor chip using linkage 
chemistry with 1-(3-(dimethylamino)propyl)-3-
ethylcarbodiimide (EDC) and N-hydroxy-succinimide 
(NHS). Unreacted EDC-NHS linkers were blocked 
with 1M ethanolamine-HCl. For all measurements, 
SPR signals in the flow cell with immobilized protein 
were subtracted with those in a flow cell that underwent 
the same manipulations but where recombinant 
protein was omitted, to obtain specific binding signals 
(response units, RU). For CFCA, recombinant mouse 
PD-L1 protein was coupled to 9920 RU, for all other 
measurements between 650 and 900 RU proteins were 
coupled. For all measurements and between each cycle, 
chips were regenerated twice with 0.5M NaCl, 15 mM 
NaOH, each time for 10 sec at 40 µl/min. CFCA was 
used to estimate the concentration of Nb in each PE and 
was performed according to manufacturer's instructions. 
Briefly, 3 different dilutions of PEs (undiluted, 10 and 
100-fold diluted in HBS) were run for 35 sec at 5 and at 
100 µL/min on a chip with high mouse PD-L1 protein 
densities and RUs were recorded. The Nbs' diffusion 
coefficient was calculated using an online tool provided 
by the company, assuming a protein globular shape, 
and ranged between 1.0 and 1.3E−10 m2/s depending on 
the theoretical Nb molecular weight. The PE dilution 
resulting in the largest difference in slope between 
the two flow speeds was used to calculate the Nb 
concentration using Biacore Evaluation software. 
The estimated Nb concentrations in the PEs 
ranged between 13 and 4900 nM and was usually around 
150 nM. Nbs, either in PEs or as purified proteins, were 
tested for affinity on immobilized mouse or human 
PD-L1 protein in SPR. To this end, 9 different Nb dilutions 
were allowed to bind to the target protein for 120 sec and 
dissociation was monitored for 160 sec. The equilibrium 
dissociation constant KD was calculated by fitting the 
obtained sensorgrams to theoretical curves, assuming 1-to-
1 binding geometries, using Biacore Evaluation software.
Mice and cell lines 
Mice deficient in PD-L1 expression (referred to as 
PD-L1 knock-out mice) were bred in-house, C57BL/6 
mice were supplied by Charles River Laboratories 
(France) at 6 weeks of age. All experiments were 
performed in accordance to the European guidelines for 
animal experimentation under a License LA1230214. 
Experiments were approved by the Ethical Committee 
for the use of laboratory animals of the Vrije Universiteit 
Brussel (15-214-1).
T.C. Wu (Johns Hopkins University, Baltimore, 
Maryland, United States of America) kindly provided 
the mouse lung epithelial cell line TC-1. TC-1 cells were 
cultured in RPMI medium, consisting of RPMI 1640 
medium (Sigma-Aldrich) supplemented with 10% FCI 
serum (Harlan), 2 mmol/L L-glutamine (L-Glu; Sigma-
Aldrich), 100 U/mL penicillin, 100 µg/mL streptomycin 
(PS; Sigma-Aldrich), 1 mmol/L sodium pyruvate and 
non-essential amino acids (Sigma-Aldrich). Lentiviral 
vectors harboring the mouse PD-L1 gene, a short hairpin 
RNA (shRNA) targeting PD-L1 or a PD-L1 targeting 
guide RNA and Cas9 were used to generate TC-1 lung 
epithelial cells in which PD-L1 was knocked-in, knocked-
down or knocked-out respectively. Lentivirus generation 
is described below.
Human embryonal kidney (HEK) 293T cells were 
purchased from the American Type Culture Collection 
(ATCC/LGC standards) and were cultured in Dulbecco’s 
modified Eagle’s medium (Sigma-Aldrich) supplemented 
with 10% FBS (Harlan), L-Glu and PS. Lentiviral vectors 
harboring the mouse or human PD-L1 gene were used 
to generate HEK293T cells expressing mouse or human 
PD-L1.
B16 cells were purchased from ATCC and cultured 
in DMEM medium, consisting of Dulbecco’s modified 
Eagle’s medium (Sigma-Aldrich) supplemented with 10% 
FBS (Harlan), L-Glu, PS and 50 µM β-mercaptoethanol. 
Lentiviral vectors harboring shRNA targeting PD-L1 were 
used to generate a B16 cell line negative for mouse PD-L1 
(PD-L1-). Parental B16 cells served as a mouse PD-L1 
positive cell line (PD-L1+).
Lentiviral vector production, characterization 
and transduction
The plasmids pCMVΔR8.9 and pMD.G were a 
gift from D. Trono (Ecole Polytechnique Fédéral de 
Lausanne, Swiss). The transfer plasmid encoding human 
PD-L1, pHR’-huPD-L1 was previously described [23]. 
The plasmid encoding mouse PD-L1, pHR’-moPD-L1, 
was generated similarly as pHR’-huPD-L1. The transfer 
plasmid harboring shRNA against mouse PD-L1 was 
previously described [56]. The mouse CD274 sgRNA 
CRISPR/Cas9 'All-in-One' lentiviral transfer vector was 
purchased from Applied Biological Materials Inc. The 
production of lentiviral vectors and their characterization 
by flow cytometry was performed as described [57]. 
Transduction of HEK293T, TC-1 and B16 cells was 
carried out at a multiplicity of infection (MOI) of 10, 
using the protocol described to transduce human dendritic 
cells [58]. Non-transduced cells are referred to as wild 
type cells. TC-1 cells transduced with lentiviral vectors 
harboring mouse PD-L1 are referred to as TC-1 PD-L1 
knock-in cells. TC-1 cells transduced with a lentiviral 
vector harboring shRNA against mouse PD-L1 are 
referred to as TC-1 PD-L1 knock-down cells and TC-1 
cells transduced with lentiviral vectors harboring CRISPR/
Cas9 targeted to mouse PD-L1 are referred to as TC-1 PD-
L1 knock-out cells. 
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Flow cytometry
Expression of PD-L1 on wild type or lentivirally 
modified HEK293T, TC-1 or B16 cells was evaluated 
using an antibody specific for mouse or human PD-L1. 
Binding of purified His-tagged Nbs or HA-tagged Nbs in 
PEs to wild type or lentivirally modified HEK293T cells 
was detected with respectively an anti-His-tag antibody 
or an anti-HA-tag antibody followed by an anti-mouse 
IgG antibody. Single cell-suspensions of spleens, lymph 
nodes, tumors and brown adipose tissue were prepared and 
expression of PD-L1 on immune cells versus non-immune 
cells was evaluated using an antibody specific for mouse 
CD45 and an antibody specific for mouse PD-L1. Cells 
were acquired on the LSRFortessa flow cytometer (BD 
Biosciences) and data were analyzed with FACSDiva (BD 
Biosciences) or FlowJo (Tristar Inc.) software.
Tumor challenge
C57BL/6 wild type and PD-L1 knock-out mice were 
injected subcutaneously with 5 x 105 TC-1 wild type, PD-L1 
knock-in, knock-down or knock-out cells. When indicated, 
mice were injected one day before tumor inoculation with 
100 µg depleting anti-CD8 antibodies (clone 2.43) or isotype 
matched control antibodies (LTF-2). The injections were 
repeated every three days. The antibodies were purchased 
from BioXcell. The tumor volume was measured thrice a 
week using an electronic caliper. The tumor volume was 
calculated using the following formula: (length × width2)/2.
99mTc-Nb labeling, pinhole SPECT-micro-CT 
imaging and image analysis
The Nbs were labeled as described by Xavier 
et al [40]. Briefly, the Nbs were coupled to the 
C-terminal His6-tag with 
99mTc-tricarbonyl intermediate 
[99mTc(H2O)3(CO)3]
99m, which was synthesized using 
the Isolink® labelling kit (Mallinckrodt Medical BV). 
The 99mTc-Nb solution was purified on a NAP-5 column 
(GE Healthcare) pre-equilibrated with PBS to remove 
unbound (99mTc(H20)3(CO)3)
+ and finally filtered through 
a 0.22 μm filter (Millipore) to remove aggregates. The 
labeling efficiency was determined both directly after 
labeling and after purifications by instant thin-layer 
chromatography (iTLC) with 100% acetone as the mobile 
phase. Mice were injected intravenously with 100 to 
200 µL of 45 to 155 MBq of 99mTc-labeled Nbs (10 µg), 
one hour prior to pinhole SPECT-micro-CT imaging. 
Imaging was performed as described [59]. Total body 
pinhole SPECT was performed once using a dual-head 
γ-camera (e.cam180; Siemens Medical Solutions), 
mounted with 2 multipinhole collimators (three 1.5 mm 
pinholes in each collimator, 200 mm focal length, and 
80 mm radius of rotation). Micro-CT was performed 
using a dual-source CT scanner (Skyscan 1178; Skyscan) 
with 60 kV and 615 mA at a resolution of 83 μm. CT 
images were reconstructed using filtered back projection 
(NRecon; Skyscan). SPECT images were reconstructed 
using an iterative reconstruction algorithm (ordered-subset 
expectation maximization) modified for the 3-pinhole 
geometry and automatically reoriented for fusion with CT 
images based on six 57Co landmarks [60]. Images were 
further visually analyzed and quantified where appropriate 
using AMIDE (Medical Image Data Examiner software) 
[61]. Quantification of tracer uptake in the center and 
at the periphery of tumors was performed using 4 cubic 
3 × 3 × 3 mm regions of Interest (ROIs) positioned on 
the 3 areas with highest uptake in the periphery and 
1 ROI positioned on area with the lowest uptake in the 
center of the tumor. For the periphery, the average of the 
3 ROI’s was calculated and represents the uptake in the 
tumor periphery. Twenty minutes after imaging, mice 
were sacrificed and all organs (including tumors when 
applicable) were isolated to measure radioactivity using a 
γ-counter (Cobra Inspector 5003, Canberra, Packard). The 
amount of radioactivity in organs is expressed as percent 
injected activity per gram (%IA/g). 
Statistics
Results are expressed as mean ± standard error of 
the mean. A non-parametric Mann-Whitney U test or One-
Way-ANOVA followed by Bonferroni multicomparison 
test was carried out to compare data sets. Sample sizes 
and number of times experiments were repeated are 
indicated in the figure legends. The number of asterisks in 
the figures indicates the statistical significance as follows: 
*P < 0.05; **P < 0.01; ***P < 0.001.
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